FDA has identified eight* priority areas where new or enhanced engagement in regulatory science research is essential to advancing its regulatory mission. These priority areas are not restricted to one product area; rather they address cross-cutting needs and opportunities that typically extend across several product areas, and where benefits and engagement from regulatory science successes will enhance product development, evaluation and health outcomes related to multiple products and populations. FDA’s strategic plan for regulatory science is critical to the continued success of the agency in meeting its regulatory mission, and to facilitate translation of breakthrough discoveries into innovative, safe and effective products of tomorrow.
* The Strategic Plan was issued in 2011. In 2013, FDA added a ninth strategic priority Strengthening the Global Product Safety Net.